Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate1)
Public ClinicalTrials.gov record NCT04146363. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a randomized, double-blind, placebo-controlled, parallel-group study which is 52 weeks in duration. The study is designed to confirm the safety and efficacy of lebrikizumab as monotherapy for treatment of moderate-to-severe atopic dermatitis utilizing a 16-week induction treatment period and a 36-week long-term maintenance treatment period.
Study identification
- NCT ID
- NCT04146363
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 424 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 12 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 23, 2019
- Primary completion
- Jun 20, 2021
- Completion
- May 2, 2022
- Last update posted
- Nov 29, 2022
2019 – 2022
United States locations
- U.S. sites
- 30
- U.S. states
- 19
- U.S. cities
- 29
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Johnson Dermatology | Fort Smith | Arkansas | 72916 | — |
| Wallace Medical Group, Inc. | Beverly Hills | California | 90211 | — |
| California Dermatology & Clinical Research Institute | Encinitas | California | 92024 | — |
| Belle Aimee Skincare Clinic | Fountain Valley | California | 92708 | — |
| Dermatology Research Associates | Los Angeles | California | 90045 | — |
| ACRC Studies | San Diego | California | 92119 | — |
| Central Connecticut Dermatology | Cromwell | Connecticut | 06416 | — |
| St. Francis Medical Institute | Clearwater | Florida | 33765 | — |
| Community Research Foundation Inc | Miami | Florida | 33145 | — |
| ForCare Clinical Research | Tampa | Florida | 33613-1244 | — |
| IACT Health - VHC | Columbus | Georgia | 31903 | — |
| The Indiana Clinical Trials Center | Plainfield | Indiana | 46168 | — |
| Skin Sciences, PLLC | Louisville | Kentucky | 40217 | — |
| Beacon Clinical Research, LLC | Quincy | Massachusetts | 02169 | — |
| Henry Ford Hospital | Detroit | Michigan | 48202 | — |
| St Joseph Dermatology and Vein Clinic | Saint Joseph | Michigan | 49085 | — |
| MediSearch Clinical Trials | Saint Joseph | Missouri | 64506 | — |
| JDR Dermatology Research | Las Vegas | Nevada | 89148 | — |
| ALLCUTIS Research | Portsmouth | New Hampshire | 03801 | — |
| Icahn Sch of Med at Mt. Sinai | New York | New York | 10029 | — |
| Sadick Research Group | New York | New York | 10075 | — |
| Wake Research Associates | Raleigh | North Carolina | 27612 | — |
| Lynn Health Science Institute | Oklahoma City | Oklahoma | 73112 | — |
| Vital Prospects Clinical Research Institute, P.C. | Tulsa | Oklahoma | 74136 | — |
| Clinical Research Institute | Medford | Oregon | 97504 | — |
| Oregon Medical Research Center | Portland | Oregon | 97223 | — |
| Clinical Partners, LLC | Johnston | Rhode Island | 02919 | — |
| Bellaire Dermatology | Bellaire | Texas | 77401 | — |
| Progressive Clinical Research | San Antonio | Texas | 78213 | — |
| Premier Clinical Research | Spokane | Washington | 99202 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 64 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04146363, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 29, 2022 · Synced Sep 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04146363 live on ClinicalTrials.gov.